Andreas Baumbach
PCRonline Editorial Board Advisor
The research in interventional cardiology focuses on improving outcomes of patients treated for acute coronary syndromes. This includes the use of novel interventional devices, the assessment of new medication during and after procedures. My interest lies in minimising the size of the heart attack and also minimising the side effects of medication used adjunctively during acute procedures. In the field of percutaneous valve implantation, I lead the pivotal trial on embolic protection during transcatheter aortic valve implantation. This technology might help to reduce the reate of stroke and subclinical cerebral infarcts during the procedure.
ACTIVITIES
- EAPCI Past-President
- Chair for Device Innovation at the Queen Mary University of London, United Kingdom since 2017.
- Director of Interventional Research, Barts Heart Centre, London - United Kingdom since 2017.
- Consultant Cardiologist at Bristol Heart Institute between 2000-2016.
Declaration of interest
| Function | Company |
|---|---|
| Other | Medtronic |
| Grants/research support | Terumo |
| Grants/research support | The Medicines Company |
Latest contributions
Calcified lesion of distal protected left main - LIVE case
22 May 2026 – From EuroPCR 2026
An 85‑year‑old man with type 2 diabetes mellitus, hypertension, dyslipidemia, peripheral artery disease, COPD, and chronic kidney disease presented with CCS class II angina related to three‑vessel coronary artery disease. He had previously undergone hybrid revascularization, including PCI of the RCA ostium and CABG with LIMA...
Aortic regurgitation in 2026
21 May 2026 – From EuroPCR 2026
Get a comprehensive overview of contemporary management strategies for aortic regurgitation, a condition that remains frequently underdiagnosed and undertreated despite significant advances in transcatheter therapies thanks to this EuroPCR 2026 session.
The programme reviews current diagnostic and treatment pathways, including guideline-based management and the role of surgical...
Complex PCI - Best cases from PCR Global Interventional Academy - Part 2
21 May 2026 – From EuroPCR 2026
This session showcases best cases from the PCR Global Interventional Academy focusing on complex PCI scenarios. It addresses challenges such as managing ostial left anterior descending artery lesions, strategies for branch protection, implications of coronary involvement during TAVI, and future directions in complex coronary interventions. The...
Expanding the horizon - Trials addressing unchartered territories in coronary and structural heart
20 May 2026 – From EuroPCR 2026
New clinical evidence is pushing coronary and structural heart therapy into areas that were previously uncertain or inconsistently defined, with multiple landmark trials now shaping future practice.
Among the studies discussed in this EuroPCR 2026 session, are SORT OUT XII, START YOUNG, BISCUSPID, LANDMARK 2 and RESTORE...
New frontiers: TAVI for aortic regurgitation with conventional and dedicated devices
20 May 2026 – From EuroPCR 2026
This session explores new frontiers in transcatheter aortic valve implantation (TAVI) for treating pure aortic regurgitation. It addresses the challenges inherent to this indication, reviews treatment approaches using conventional balloon-expandable and self-expandable devices, and presents recent data along with dedicated TAVI devices designed specifically for aortic...
PCR Global Interventional Academy
20 May 2026
This one-of-a-kind academy offers independent, cutting-edge training pathways for ambitious interventionalists who have been in practice for a few years and are looking to grow - both personally and professionally. Two recurrent high-level one-year tracks on coronary interventions and TAVI are already underway, with further opportunities forecast for...
Beyond the horizon - A prelude into TAVI and complex PCI solutions
19 May 2026 – From EuroPCR 2026
This session provides a comprehensive preview of evolving technologies and strategies shaping interventional cardiology. Discover the Myval Octapro+ transcatheter heart valve (THV) and its innovative design and procedural benefits demonstrated through a recorded case. Stay updated on Landmark and Compare TAVI trial data, and discover the...
Building evidences to address current challenges in the treatment of aortic stenosis
21 May 2026 – From EuroPCR 2026
At EuroPCR 2026, Andreas Baumbach, Philippe Garot and Rutger-Jan Nuis discuss three important trials that could help shape the future management of aortic stenosis.
The BASELINE trial compares self-expanding and balloon-expandable valves in patients undergoing valve-in-valve TAVI for a failing surgical bioprosthesis. The START YOUNG trial focuses...
What are the latest developments in TAVI for aortic regurgitation?
21 May 2026 – From EuroPCR 2026
Andreas Baumbach and Raj Makkar explore the latest developments in TAVI for aortic regurgitation. They review the emergence of dedicated transcatheter devices designed for patients with symptomatic aortic regurgitation who are at high surgical risk or unsuitable for surgery, and discuss the evidence supporting their use.
The conversation...
Integrate solutions to address current challenges in the treatment of complex PCI
19 May 2026 – From EuroPCR 2026
At EuroPCR 2026, Ashok Seth, Andreas Baumbach and Sasko Kedev discuss how the management of complex coronary artery disease has evolved over the past decade.
As patient and lesion complexity continues to increase, operators are faced with challenges ranging from severe calcification and renal dysfunction to diabetes...
TAVI in aortic regurgitation - Part 2
17 Nov 2025 – From PCR London Valves 2025
This session focuses on transcatheter aortic valve implantation in the setting of aortic regurgitation, a challenging clinical entity. It features novel techniques such as pump-assisted deployment and the use of deflectable self-expanding systems, as well as management of patients with prior valve-sparing aortic root surgery and...
New approaches in aortic regurgitation
16 Nov 2025 – From PCR London Valves 2025
Explore new diagnostic and therapeutic approaches for managing aortic regurgitation. This session covers imaging modalities, guideline-directed patient selection, current transcatheter treatment techniques, and emerging TAVI technologies designed specifically for non-calcific aortic valve pathology.
TAVI and aortic valve procedures
11 Oct 2025 – From AICT-AsiaPCR 2025
Focusing on transcatheter aortic valve interventions, this session covers a broad spectrum of complex cases including emergent TAV-in-SAV procedures, management of severely calcified bicuspid valves, zero-contrast TAVI techniques, and strategies for hostile anatomies. It provides valuable insights into procedural planning and follow-up to optimize patient care...
Complex non left main bifurcation - LIVE Case
11 Oct 2025 – From AICT-AsiaPCR 2025
A 55-year-old male with no risk factors presented with an anterior STEMI treated by primary PCI of the LAD. Coronary angiography revealed triple-vessel disease. The RCA was treated one month later with a DCB, and the bifurcation LCX/OM (Medina 1,1,1) was treated during the live procedure....
Valve-in-valve in degenerated surgical bioprothesis mitral valve - LIVE Case
10 Oct 2025 – From AICT-AsiaPCR 2025
A 78-year-old male with a history of rheumatic disease underwent surgical mitral valve replacement (Perimount Magna 25), surgical aortic valve replacement (Perimount Magna), and CABG (LIMA–LAD) in 2010. He presented with symptomatic severe mitral regurgitation and normal LV function.
He was treated with implantation of a 26...
Innovations in transcatheter aortic valve devices and techniques
22 May 2025 – From EuroPCR 2025
Explore the latest advancements in transcatheter aortic valve devices and innovative procedural techniques. This session presents initial clinical experiences with new self-expandable valves in small annuli, safety and performance data from the GENESIS-II study on the Hydra valve, and up to 12-month outcomes from the Valvosoft...
The Landmark RCT - One-year results
21 May 2025 – From EuroPCR 2025
This session presents a detailed analysis of a landmark randomized controlled trial evaluating the Myval transcatheter aortic valve implantation (TAVI) system among other contemporary transcatheter valves. The discussion centers on one-year clinical outcomes, with a particular focus on women, patients with small aortic annuli, and those...
Complex multivessel disease - LIVE Case
21 May 2025 – From EuroPCR 2025
An 89-year-old male patient presented with stable angina, preserved LV function and some risk factors such as hypertension and diabetes. CT scan and angiography revealed occlusion of proximal RCA and bifurcation lesions on LAD and circumflex (medina 1,1,1). Operators treated the bifurcation lesions with provisional stenting.
Regarding...
Myval Octapro THV - Optimise patient outcomes with novel design, data and daily clinical practice
21 May 2025 – From EuroPCR 2025
This session presents the latest updates on the novel Myval Octapro transcatheter heart valve (THV), based on one year of real-world clinical experience. Experts share practical tips and clinical cases that highlight how this innovative device can improve TAVI patient outcomes. The session also addresses imaging and...
EAPCI Fellowship Grant Awards
21 May 2025 – From EuroPCR 2025
Celebrate the achievements of emerging cardiology leaders with the EAPCI Fellowship Grant Awards session. This presentation highlights the awarded fellows' contributions and the impact of fellowship support on advancing interventional cardiology research and clinical practice.
What is new in atrioventricular valves?
19 May 2025 – From EuroPCR 2025
Discover the latest advancements in atrioventricular valve interventions, including innovative transcatheter repair technologies and first-in-human experiences with novel devices.
Learnings from LANDMARK and Compare-TAVI at 3 years
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Andreas Baumbach, Christian Juhl Terkelsen and Didier Tchetche reviewed the latest findings from the LANDMARK and Compare-TAVI 1 trials—both focused on the performance of the Myval balloon-expandable valve.
LANDMARK compared Myval and Myval Octacor to leading self-expanding valves in a randomised controlled trial. At...
Focus on drug coated balloons: evidence and practice
07 Jan 2025
This Special Report led by Andreas Baumbach explores the history, current techniques, evidence, and future of DCBs, plus insights on left main stent restenosis.
Best of science and education in cardiovascular interventional medicine in 2024
16 Dec 2024
Dear Colleagues, dear PCR Companions,
As we welcome a new year, it is the perfect time to reflect on what we achieved together over the past year—both as a celebration of our successes and as motivation to continue improving in the year ahead.
2024 was a record year...
Editorial: Focus on Drug-Coated Balloons (DCB) in clinical practice
19 Dec 2024
DCBs have undergone extensive development to meet the challenges of minimizing restenosis and maintaining vessel patency. Unlike stents, DCBs deliver an antiproliferative drug directly to the arterial wall without leaving a permanent implant. This approach has proven effective in treating small-vessel disease, in-stent restenosis, and de...
Author
TAVI for pure aortic regurgitation with a dedicated CE-mark device: an underdiagnosed and undertreated disease
26 Nov 2024 – From PCR London Valves 2024
Explore this session to learn about the unmet needs in aortic regurgitation (AR) and the performance of dedicated TAVI devices for AR. Discover why new thresholds for severe AR are necessary, and how traditional methods may underestimate its severity. Gain insights into the TRILOGY THV system,...
TAVI for aortic regurgitation
25 Nov 2024 – From PCR London Valves 2024
Curious about advancing your knowledge in TAVI for aortic regurgitation? Don’t miss this video!
You'll dive into the diagnostic and treatment strategies to optimize outcomes in patients with aortic regurgitation, explore groundbreaking technologies like the Jenavalve Trilogy THV system and gain insights from the latest clinical evidence and...
TAVI for pure aortic regurgitation - LIVE case
25 Nov 2024 – From PCR London Valves 2024
Watch a LIVE case followed by a recorded case on aortic regurgitation:
- An 86-year-old male with a history of stroke and prostate cancer presenting acute heart failure due to severe pure aortic regurgitation and LV dysfunction (EF 39%). A 27 mm JenaValve Trilogy prosthesis was implanted without...
Align for the future with Myval THV series - From randomised trials to everyday clinical practice
25 Nov 2024 – From PCR London Valves 2024
Through the presentation of several compelling cases, including an 88-year-old male with CKD, RBBB, moderate LV dysfunction, and severe aortic stenosis, a Type 1a bicuspid native AS, and an extraordinary TAVI in an 83-year-old with acute heart failure and comorbidities, this session will dive into the...
Rendez-vous with Myval THV series and Landmark RCT subset analysis
24 Nov 2024 – From PCR London Valves 2024
Discover this interactive session during which the audience learns about and discusses the novel Myval THV Series, a series of valves featuring intermediate and XL sizes. They also discuss the results of the pivotal LANDMARK randomized controlled trial and its relevance in clinical practice.
